MOMuhammad Osman

Muhammad Osman

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Muhammad Osman has a total of 153 co-authors. Here are the top co-authors by number of shared publications:

  • Rory Dunbar

    Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa

    7 shared publications
  • Anneke C. Hesseling

    Affiliation Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa

    6 shared publications
  • James A. Seddon

    Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa

    6 shared publications
  • Pren Naidoo

    Affiliation Public health Management Consultant, Cape Town, South Africa

    6 shared publications
  • Alex Welte

    DSI-NRF South African Centre of Excellence in Epidemiological Modelling and Analysis (SACEMA), Stellenbosch University, Stellenbosch, South Africa

    5 shared publications
  • Anneke C Hesseling

    Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa

    5 shared publications

Latest Publications

  • Open Access

    An economic evaluation of the LINKEDin study: An intervention to reduce initial loss to follow-up among tuberculosis patients in South Africa

    by Michael Strauss, Muhammad Osman, Sue-Ann Meehan, Florian M. Marx, Anneke C. Hesseling, Andrew Boulle, Pren Naidoo, Gavin George

    Tuberculosis (TB) patients who are diagnosed but not registered and initiated on TB treatment are categorised as initial loss to follow-up (ILTFU). ILTFU is a key driver of morbidity and mortality associated with TB and is a contributing factor to high TB transmission rates. LINKEDin was a quasi-experimental study which evaluated two specific interventions for reducing ILTFU in three high-TB burden provinces in South Africa, conducted from October 2018 to December 2020. As part of LINKEDin, we undertook a micro-costing from the healthcare provider perspective using an activity-based costing approach. Cost estimates included the cost of the operation of an integrated provincial health data centre in the Western Cape, apportioned to the TB activities it supported in the province. Cost estimates were linked to intervention outcomes to understand the incremental cost of the intervention per additional patient linked to care compared to rates of ILTFU in the absence of the interventions. Sensitivity analyses were conducted to account for uncertainty in the intervention outcomes, and for periods where the implementation of the intervention was interrupted due to COVID-19 related disruptions. Costing data were collected between August 2020 and March 2021. The total cost of implementing the LINKEDin intervention in the WC and KZN was $7 534.42 per month. The cost of implementing LINKEDin in the Western Cape accounted for 56% the total cost of the intervention – 8% from the operations of the PHDC and 48% from the cost of running the intervention – while only 44% of the total cost was accounted for by the intervention run in KwaZulu-Natal. The primary cost driver of the interventions were staff salaries, with the cost of data extraction and in-hospital activities low relative to primary healthcare (PHC)-based follow-up activities. In terms of cost effectiveness, the LINKEDin interventions in KZN was cost $377.28 per additional person linked to care, and $243.62 in the WC, per additional person linked to care. In the Western Cape, systematically tracking persons with TB using an automated system proved highly cost efficient compared to the more labour intense approach adopted in KwaZulu-Natal. Optimising the curation and management of data and increasing the effectiveness of tracing systems and processes can result in cost-savings.

  • Open Access

    Lessons from a systematic tracing process aimed to reduce initial loss to follow-up (ILTFU) among people diagnosed with tuberculosis (TB) in Cape Town, South Africa

    by Nosivuyile Vanqa, Lario Viljoen, Graeme Hoddinott, Anneke Hesseling, Muhammad Osman, Sue-Ann Meehan

    Background: South Africa is a high tuberculosis (TB) burdened country. People who are newly diagnosed with TB must link to a TB treatment facility and be registered in the electronic TB notification system for ongoing care. Delayed linkage to care increases the risk of disease progression, mortality, and ongoing TB transmission. We describe lessons from a systematic tracing process aimed to support linkage to care for people diagnosed with TB. Methods: The study used the Western Cape Provincial Health Data Centre (PHDC) to identify persons newly diagnosed with TB (January-December 2020) who were not recorded as linked to care after routine linking efforts, in one peri-urban health sub-district in Cape Town, South Africa. A systematic tracing process was followed, including visits to primary health care (PHC) facilities, and home visits for those with no evidence of linkage at PHC level. Descriptive statistics were used to analyse quantitative data. Lessons learned during the process were documented. Results: Within the PHDC, 406 persons diagnosed with TB had no evidence of being linked to TB care. Verification at PHC facilities found that 153/406 (38%) had linked to care. We traced 219 persons; of which107 (49%) could not be found. Overall, the PHDC showed 76% linkage among those traced and found and 72% among those not found. Lessons learned include the need for improved; (i) record keeping enabling the allocation of resources to patients who are truly lost to follow up, (ii) communication to improve patient understanding of timely treatment initiation and (iii) interpersonal relationships to encourage trust. Conclusion: The systematic tracing process was useful to understand the complexities around delayed linkage to care. To reduce ILTFU, we recommend, improving accuracy and timely recording of TB data, updating patient contact details regularly and strengthening interpersonal relations and communication between patients and healthcare workers.


  • Open Access

    Reducing Initial Loss to Follow-up Among People With Bacteriologically Confirmed Tuberculosis: LINKEDin, a Quasi-experimental Study in South Africa

    by Sue-Ann Meehan, Anneke C Hesseling, Andrew Boulle, Jolene Chetty, Lucy Connell, Nomthandazo J Dlamini-Miti, Rory Dunbar, Karen Du Preez, Gavin George, Graeme Hoddinott, et al.

    Every person diagnosed with tuberculosis (TB) needs to initiate treatment. The WHO estimated 61% of people who developed TB in 2021 were included in a TB treatment registration system. Initial loss to follow up (ILTFU) is the loss of persons to care between diagnosis and treatment initiation/registration. LINKEDin, a quasi-experimental study, evaluated the effect of two interventions (hospital-recording and an alert-and-response patient management intervention) in six sub-districts across three high-TB burden provinces of South Africa. Using integrated electronic reports, we identified all persons diagnosed with TB (Xpert MTB/RIF positive) in hospital and at primary healthcare facilities. We prospectively determined linkage to care at 30 days after TB diagnosis. We calculated the risk of ILTFU during the baseline and intervention periods and the relative risk reduction in ILTFU between these periods. We found a relative reduction in ILTFU of 42.4% (95%CI:28.5,53.7) in KwaZulu Natal (KZN) and 22.3% (95%CI:13.3,30.4) in the Western Cape (WC) with no significant change in Gauteng. In KZN and the WC, the relative reduction in ILTFU appeared greater in sub-districts where the alert-and-response patient management intervention was implemented; KZN (49.3% (95%CI:32.4,62) vs 32.2% (95%CI:5.4,51.4)); and WC (34.2% (95%CI:20.9,45.3) vs 13.4% (95%CI:0.7,24.4)). We reported a notable reduction in ILTFU in two provinces using existing routine health service data and applying a simple intervention to trace and recall those not linked to care. TB programs need to consider ILTFU as a priority and develop interventions specific to their context to ensure improved linkage to care.


  • Open Access

    A systematic review of risk factors for mortality among tuberculosis patients in South Africa

    by Tamaryn J Nicholson, Graeme Hoddinott, James A Seddon, Mareli M Claassens, Marieke M van der Zalm, Elisa Lopez, Peter Bock, Judy Caldwell, Dawood Da Costa, Celeste de Vaal, et al.

    Background: Tuberculosis (TB)-associated mortality in South Africa remains high. This review aimed to systematically assess risk factors associated with death during TB treatment in South African patients. Methods: We conducted a systematic review of TB research articles published between 2010 and 2018. We searched BioMed Central (BMC), PubMed®, EBSCOhost, Cochrane, and SCOPUS for publications between January 2010 and December 2018. Searches were conducted between August 2019 and October 2019. We included randomised control trials (RCTs), case control, cross sectional, retrospective, and prospective cohort studies where TB mortality was a primary endpoint and effect measure estimates were provided for risk factors for TB mortality during TB treatment. Due to heterogeneity in effect measures and risk factors evaluated, a formal meta-analysis of risk factors for TB mortality was not appropriate. A random effects meta-analysis was used to estimate case fatality ratios (CFRs) for all studies and for specific subgroups so that these could be compared. Quality assessments were performed using the Newcastle-Ottawa scale or the Cochrane Risk of Bias Tool. Results: We identified 1995 titles for screening, 24 publications met our inclusion criteria (one cross-sectional study, 2 RCTs, and 21 cohort studies). Twenty-two studies reported on adults (n = 12561) and two were restricted to children < 15 years of age (n = 696). The CFR estimated for all studies was 26.4% (CI 18.1–34.7, n = 13257 ); 37.5% (CI 24.8-50.3, n = 5149) for drug-resistant (DR) TB; 12.5% (CI 1.1–23.9, n = 1935) for drug-susceptible (DS) TB; 15.6% (CI 8.1–23.2, n = 6173) for studies in which drug susceptibility was mixed or not specified; 21.3% (CI 15.3-27.3, n = 7375) for people living with HIV/AIDS (PLHIV); 19.2% (CI 7.7–30.7, n = 1691) in HIV-negative TB patients; and 6.8% (CI 4.9–8.7, n = 696) in paediatric studies. The main risk factors associated with TB mortality were HIV infection, prior TB treatment, DR-TB, and lower body weight at TB diagnosis. Conclusions: In South Africa, overall mortality during TB treatment remains high, people with DR-TB have an elevated risk of mortality during TB treatment and interventions to mitigate high mortality are needed. In addition, better prospective data on TB mortality are needed, especially amongst vulnerable sub-populations including young children, adolescents, pregnant women, and people with co-morbidities other than HIV. Limitations included a lack of prospective studies and RCTs and a high degree of heterogeneity in risk factors and comparator variables. Systematic review registration: The systematic review protocol was registered in the International Prospective Register of Systematic Reviews (PROSPERO) under the registration number CRD42018108622. This study was funded by the Bill and Melinda Gates Foundation (Investment ID OPP1173131) via the South African TB Think Tank.


  • Open Access

    The prevalence of pulmonary hypertension after successful tuberculosis treatment in a community sample of adult patients

    by Elizabeth Louw, Nicola Baines, Gerald Maarman, Muhammad Osman, Lovemore Sigwadhi, Elvis Irusen, Coenraad Koegelenberg, Anton Doubell, Steven Nathan, Richard Channick, et al.

    There are an estimated 155 million survivors of tuberculosis (TB). Clinical experience suggests that post tuberculosis lung disease (PTLD) is an important cause of Group 3 pulmonary hypertension (PH). However, TB is not listed as a cause of PH in most guidelines. A cross‐sectional, community‐based study was conducted in nonhealthcare seeking adults who had successfully completed TB treatment. Subjects underwent questionnaires, spirometry, a 6‐min walk distance test (6MWD) and transthoracic echocardiography (TTE). Screen probable PH was defined on TTE as an estimated pulmonary artery peak systolic pressure (PASP) of ≥40 mmHg. One hundred adults (71 males) were enrolled, with a mean age of 42 years (SD 13.8 years) and a median of one TB episode (interquartile range: 1–2). Co‐morbidities included hypertension (21%), diabetes (16%), human immunodeficiency virus (10%) and asthma/COPD (5%). Only 25% had no residual symptoms after TB. Probable PH was found in 9%, while 7% had borderline raised PASP values (PASP 35–40 mmHg). An association was found between PH and the number of previous TB episodes, with each additional episode of TB increasing the odds of PH‐postTB 2.13‐fold (confidence interval [CI]: 1.17–3.88; p = 0.013). All of those found to have PH were smokers or ex‐smokers yielding an unadjusted odds ratio for PH‐postTB of 3.67 (95% CI: 0.77–17.46). There was no statistical difference in spirometry or 6MWD, between those with and without PH. Neither symptoms nor co‐morbidities demonstrated significant association with PH. PH after TB was a common finding in this community‐based population. Further research is needed to confirm and determine the significance of these findings.


  • Open Access

    Toward a conceptual framework of the acceptability of tuberculosis treatment in children using a theory generative approach

    by Dillon T Wademan, Megan Palmer, Susan Purchase, Marieke M van der Zalm, Muhammad Osman, Anthony J Garcia-Prats, James A Seddon, H Simon Schaaf, Anneke C Hesseling, Ria Reis, et al.

    To describe an early-stage holistic framework towards evaluating factors that impact the overall acceptability of TB treatment along the TB care cascade in children. We developed a conceptual framework utilising a theory generative approach. Domains were developed through review of existing definitions and analysis of existing qualitative data undertaken in acceptability studies of TB treatment in children. Clarity of domain definitions was achieved through iterative refinement among the research team. Three domains, each comprising several dimensions, were identified to holistically evaluate treatment acceptability: (1) usability, which involves the alignment between the requirements of treatment use and caregivers’ and children’s ability to integrate TB treatment into their everyday routines, (2) receptivity, which describes the end-user’s perception and expectations of treatment and its actual use, and (3) integration, which describes the relationship between available health services and caregivers/children’s capacity to make use of those services. Our framework addresses the gaps in current research which do not account for the influence of caregivers’ and children’s contexts on TB treatment uptake and overall acceptability. This approach may support the development of more standard, holistic measures to improve TB treatment delivery and experiences and future research in children.


  • Open Access

    LAPAROSCOPIC EXPLORATION OF COMMON BILE DUCT WITH PRIMARY CLOSURE VERSUS T-TUBE DRAINAGE

    by Specialist Registrar St7 General & Colorectal Surgery Royal Bolton Hospital Nhs Foundation Trust., Muhammad Osman, Muhammad Iftikhar, Assistant ProfessorGeneral Surgery Department Hayatabad Medical Complex Peshawar Pakistan., Zia Ullah, Medical Officer Hayatabad Medical Complex Peshawar Pakistan.

    Background: Laparoscopic exploration of the common bile duct followed by T-tube has long been a standard surgical treatment for choledocholithiasis. However the use of T-tube is not without complications. To avoid these complications we have performed primary closure of the common bile duct (CBD) after laparoscopic exploration. Objective: To assess the benefits and harms of T-tube drainage versus primary closure after laparoscopic common bile duct exploration. Material and methods:This is a comparative study carried out at General Surgical Deptt of Hayatabad Medical Complex Peshawar Pakistan from 6-6-2019 to 6-6-2021. Total 34 patients for laparoscopic exploration of the common bile duct were included in the study. Results:The length of mean postoperative hospital stay was muchshorteringroupA(4.5 ± 1.4) thaningroupB(7.2 ± 1.6).Thehospitalization expenses were statistically lower in group A (15150.0 ± 2160.5) than in group B (19798.1 ± 2485.5). No significant difference was observed in the operating time in both groups i.e. (128.3 ± 25.9) in group A & (133.9 ± 26.7). Intraoperative blood loss were also shows no significant difference amongst both groups, (101.3 ± 56.1) in group A & (103.9 ± 60.2). Bile leakage rate in group A is 2(5.8%) and in group B 3(8.8%), intraabdominal bleeding 1(2.9%) & 1(2.9%), pulmonaryinfection were 2(5.8%) & 1(2.9%), intra-abdominal infection were 2(5.8%) & 3(8.8%), gastroduodenal serosal injury 0 (0%) & 0 (0%), wound infection 1 (2.9%) & 1 (2.9%), stone recurrence 2(5.8%) & 2(5.8%) and bile stricture seen in 0 (0%) in group A & 1 (2.9%) in group B respectively. Table II Conclusion:Primary closure of the CBD is a safe and cost effective alternative to routine T-tube drainageafter Laparoscopic exploration.

  • Open Access

    The Impact of HIV and Tuberculosis Interventions on South African Adult Tuberculosis Trends, 1990-2019: A Mathematical Modelling Analysis

    by Mmamapudi Kubjane, Muhammad Osman, Andrew Boulle, Leigh F. Johnson

    Background: The South African tuberculosis epidemic is largely driven by HIV. Interventions including directly observed therapy (DOTS), antiretroviral therapy (ART), isoniazid preventative therapy (IPT), increased tuberculosis screening, and Xpert MTB/RIF have been implemented to control the tuberculosis burden. This study aimed to estimate the impact of HIV and interventions on the South African tuberculosis epidemic between 1990 and 2019. Methods: A dynamic tuberculosis transmission model for South Africa was developed. A Bayesian approach was used to calibrate the model to the numbers of people starting treatment, tuberculosis deaths, microbiological tests, and a national tuberculosis prevalence survey. Counterfactual scenarios were simulated to estimate tuberculosis incidence and mortality attributable to HIV, and the impact of interventions on tuberculosis incidence. Findings: Between 1990 and 2019, 8·8 million (95% confidence interval (CI) 8·3–9·3 million) people developed tuberculosis, and 2·1 million (95% CI 2·0–2·2 million) died from tuberculosis. 55% and 69% of the tuberculosis incidence and mortality respectively were due to HIV. Overall, tuberculosis screening and ART had a substantial impact, reducing tuberculosis incidence by 28·2% (95% CI 26·4–29·8%) and 20·0% (95% CI 19·2–20·7%) respectively, in 2019; IPT, DOTS and Xpert MTB/RIF had minor impacts. Interpretation: HIV has heightened tuberculosis incidence and mortality. The provision of ART and intensification of tuberculosis screening explain most declines in tuberculosis incidence between 2005 and 2019. Continued efforts are therefore required to strengthen these interventions. There is a need for improved diagnostics and preventative therapy to accelerate progress towards ending the tuberculosis epidemic. Funding: National Institutes of Health, South African National Research Foundation, and Bill and Melinda Gates Foundation Declaration of Interest: We declare no competing interests.

  • Top Cited Papers
    Open Access

    The global burden of tuberculous meningitis in adults: A modelling study

    by Peter J. Dodd, Muhammad Osman, Fiona V. Cresswell, Anna M. Stadelman, Nguyen Huu Lan, Nguyen Thuy Thuong Thuong, Morris Muzyamba, Lisa Glaser, Sicelo S. Dlamini, James A. Seddon

    Tuberculous meningitis (TBM) is the most lethal form of tuberculosis. The incidence and mortality of TBM is unknown due to diagnostic challenges and limited disaggregated reporting of treated TBM by existing surveillance systems. We aimed to estimate the incidence and mortality of TBM in adults (15+ years) globally. Using national surveillance data from Brazil, South Africa, the United Kingdom, the United States of America, and Vietnam, we estimated the fraction of reported tuberculosis that is TBM, and the case fatality ratios for treated TBM in each of these countries. We adjusted these estimates according to findings from a systematic review and meta-analysis and applied them to World Health Organization tuberculosis notifications and estimates to model the global TBM incidence and mortality. Assuming the case detection ratio (CDR) for TBM was the same as all TB, we estimated that in 2019, 164,000 (95% UI; 129,000–199,000) adults developed TBM globally; 23% were among people living with HIV. Almost 60% of incident TBM occurred in males and 20% were in adults 25–34 years old. 70% of global TBM incidence occurred in Southeast Asia and Africa. We estimated that 78,200 (95% UI; 52,300–104,000) adults died of TBM in 2019, representing 48% of incident TBM. TBM case fatality in those treated was on average 27%. Sensitivity analysis assuming improved detection of TBM compared to other forms of TB (CDR odds ratio of 2) reduced estimated global mortality to 54,900 (95% UI; 32,200–77,700); assuming instead worse detection for TBM (CDR odds ratio of 0.5) increased estimated mortality to 125,000 (95% UI; 88,800–161,000). Our results highlight the need for improved routine TBM monitoring, especially in high burden countries. Reducing TBM incidence and mortality will be necessary to achieve the End TB Strategy targets.